Preliminary evaluation of a bunyavirus vector for cancer immunotherapy
Files
Publication date
2015-01-01
Authors
Oreshkova, N.
Spel, Lotte
Vloet, R. P M
Wichgers Schreur, P. J.
Moormann, R. J M
Boes, Marianne
Kortekaas, J.
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
Abstract
Replicon particles of Rift Valley fever virus, referred to as nonspreading Rift Valley fever virus (NSR), are intrinsically safe and highly immunogenic. Here, we demonstrate that NSR-infected human dendritic cells can activate CD8<sup>+</sup> T cells in vitro and that prophylactic and therapeutic vaccinations of mice with NSR encoding a tumor-associated CD8 peptide can control the outgrowth of lymphoma cells in vivo. These results suggest that the NSR system holds promise for cancer immunotherapy.
Keywords
Immunology, Virology
Citation
Oreshkova, N, Spel, L, Vloet, R P M, Wichgers Schreur, P J, Moormann, R J M, Boes, M & Kortekaas, J 2015, 'Preliminary evaluation of a bunyavirus vector for cancer immunotherapy', Journal of Virology, vol. 89, no. 17, pp. 9124-9127. https://doi.org/10.1128/JVI.01105-15